Eli Lilly said it has begun selling single-dose vials of its popular weight-loss drug Zepbound in the U.S., aiming to meet intense demand for the obesity medication. Amandalina Letterio has the details and more in Health Matters for Aug. 27, 2024.
- Higher doses of Zepbound to be offered on Eli Lilly website
- Zepbound beats Wegovy rival in 1st head-to-head weight loss study